CJC-1295 Effect on IGF-1: Direction, Magnitude, Time Course, and Monitoring

Does CJC-1295 raise IGF-1? The direct answer

Yes. CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It binds GHRH receptors on pituitary somatotroph cells and amplifies the pulses of growth hormone (GH) the pituitary already releases. The liver converts a portion of that additional GH into insulin-like growth factor 1 (IGF-1), which is why IGF-1, not GH itself, is the biomarker clinicians track. This mechanism is standard endocrine physiology and is not in dispute. What is less settled, and is the actual point of confusion for most readers, is how large the IGF-1 rise typically is, how fast it happens, and what specific numeric benchmarks in circulation can actually be trusted.

CJC-1295 does not have an FDA-approved indication. It is used off-label or as a compounded preparation through 503A pharmacies, and the evidence base behind its dosing and monitoring in clinical practice is thinner than for FDA-approved growth hormone therapies such as recombinant human GH (rhGH).

Why IGF-1, and not GH, is the lab to watch

GH is secreted in pulses roughly every 90 to 120 minutes, so a single random GH blood draw reflects only a momentary snapshot and is not clinically interpretable. IGF-1 circulates bound to IGF-binding protein-3, has a much longer half-life measured in hours rather than minutes, and integrates GH exposure over roughly a day or two. That stability is why IGF-1, not GH, is the standard monitoring marker for any GH-axis therapy, a principle used in guideline-based monitoring of FDA-approved GH replacement and generally extended by prescribers to GH secretagogues, even though the guidelines were written for rhGH rather than for secretagogues specifically.

The DAC and no-DAC formulations behave differently, and that changes monitoring

CJC-1295 exists in two forms, and confusing them leads to mistimed labs and dosing.

No-DAC (often labeled "Modified GRF 1-29") has a functional half-life of roughly 30 minutes. It is typically injected two to three times daily to mimic physiologic GH pulsing. Because each dose clears quickly, IGF-1 does not reflect a single injection; it reflects the cumulative effect of consistent dosing over roughly three to four weeks.

DAC-conjugated CJC-1295 binds serum albumin, extending its half-life to several days. A single injection produces a sustained rather than pulsatile GH elevation, and weekly dosing is the typical protocol. A widely cited phase 2 study of CJC-1295 with DAC (commonly attributed to Teichman et al., published in 2006) reportedly found that GH and IGF-1 remained elevated for up to about two weeks after a single dose, with the effect described as dose-dependent. That general shape of the finding is consistent with what would be expected from an albumin-bound GHRH analogue, but the specific numeric figures attached to this trial in secondary sources, including exact percentage increases at specific dose levels, could not be verified against the original publication for this article. Anyone relying on a precise number from this trial for a dosing or monitoring decision should pull the primary paper first rather than trust a secondhand percentage.

Clinicians ordering IGF-1 labs should document which formulation a patient is using, because the two produce meaningfully different IGF-1 trajectories and require different recheck timing.

Time course: when IGF-1 actually moves

No-DAC, twice-daily dosing:

• Days 1 to 3: GH pulses are already amplified, but IGF-1 has not accumulated enough to be a meaningful steady-state value. A lab drawn this early is not interpretable.
• Days 5 to 14: IGF-1 typically begins to rise measurably.
• Weeks 3 to 6: IGF-1 generally approaches a new steady state. This is the practical window for a first meaningful recheck.
• Beyond week 12: IGF-1 tends to remain stable on a consistent dose; periodic rechecks (roughly every six months) are reasonable for patients continuing therapy long-term.

DAC-conjugated, weekly dosing:

• IGF-1 is often measurably above baseline within about a week of the first dose and more clearly established after the second weekly dose.
• Because the elevation is sustained rather than pulsatile, checking IGF-1 midway between injections (for example, day 3 or 4 of a weekly cycle) avoids capturing a transient post-injection peak that may not represent average exposure.

These intervals reflect general pharmacokinetic reasoning about a slow-clearance versus fast-clearance peptide, combined with common practice among prescribers of GH secretagogues. They are not derived from a validated, published monitoring trial specific to CJC-1295, and should be treated as a reasonable starting framework rather than a fixed rule.

What moves IGF-1 besides the peptide itself

IGF-1 is sensitive to more than just GH secretagogue dose, and misreading these confounders is a common source of unnecessary dose changes:

• Nutrition. Caloric restriction and low protein intake independently suppress IGF-1. A patient losing weight, including on concurrent GLP-1 therapy, may show a blunted IGF-1 rise despite adequate GH stimulation.
• Thyroid function. Hypothyroidism suppresses hepatic IGF-1 production and can mask a genuine therapeutic response.
• Sex hormones. Testosterone and estrogen both influence hepatic GH receptor sensitivity. Starting or stopping testosterone or hormone therapy at the same time will shift IGF-1 independent of the peptide dose.
• Insulin resistance and obesity. Visceral adiposity blunts baseline GH secretion, which can make percentage increases look larger from a lower starting point while also making the response less predictable.
• Draw conditions. IGF-1 is more stable across the day than GH, but a consistent, fasting morning draw is standard practice for comparing serial results.

A practical decision framework for IGF-1 monitoring

This is a general decision-support framework built from the physiology and confounders above. It is not a validated clinical protocol from a trial or professional guideline, and it does not replace individualized medical judgment. It is meant to help a clinician or an informed patient structure the conversation, not to set a dose.

Step 1: Establish baseline before any dosing decision. Draw a fasting morning IGF-1, and note age, sex, and the lab's own reference range, since IGF-1 reference intervals are age- and sex-stratified and vary by assay.

Step 2: Classify the starting point.

Step 3: Recheck at a time that matches the formulation's kinetics, not a fixed calendar date. No-DAC formulations need three to six weeks to reach a meaningful steady state; DAC formulations show change within roughly two weeks.

Step 4: Treat two consecutive above-range results, not one, as the trigger for a clinical decision. A single elevated value can reflect assay variability, a mistimed draw relative to a DAC injection, or a transient confounder. Repeat testing before changing course.

Step 5: Rule out non-peptide explanations before attributing an abnormal IGF-1 to the dose. Thyroid status, weight change, and sex hormone changes should be checked before assuming the peptide dose is the sole driver.

Exception: any new symptoms suggestive of soft-tissue overgrowth, joint pain, carpal tunnel symptoms, or new glucose intolerance warrant prompt clinical evaluation regardless of where the IGF-1 number falls, and are not something this framework, or any lab-driven schedule, should be relied on to catch on its own.

Combining CJC-1295 with other secretagogues

CJC-1295 (modified GRF) acts on the GHRH receptor. Ipamorelin, a separate class of GH secretagogue, acts on the ghrelin receptor (GHSR). Because they work through different receptors, combining them is reported to produce an additive GH and IGF-1 effect greater than either agent alone in typical peptide-clinic practice. Specific percentage estimates of that additive effect are not well documented in verifiable primary literature and should be treated as approximate. The practical implication is that combination regimens carry a higher chance of pushing IGF-1 above the upper limit of normal, which argues for more frequent monitoring, not less, when agents are combined.

Sermorelin, an older GHRH analogue using the native 29-amino-acid sequence without the enzyme-resistant substitutions found in CJC-1295, has a shorter functional half-life and is generally understood to produce a smaller IGF-1 effect for an equivalent injection frequency. This is a reasonable inference from the two molecules' pharmacokinetics rather than a head-to-head trial finding.

Safety: what elevated IGF-1 means, and what is not established

Chronically elevated IGF-1 activates growth-signaling pathways in cells, and epidemiologic studies have associated higher-normal to elevated IGF-1 with increased risk of certain cancers, including colorectal, prostate, and breast cancer. This is observational, correlational evidence; a causal link has not been established in interventional trials, and readers should not treat this as proof that a given IGF-1 elevation from CJC-1295 causes cancer. It is a reason for caution and monitoring, not a reason for alarm at a single mildly elevated result.

FDA-approved somatropin (rhGH) prescribing information includes a warning about neoplasia risk associated with GH therapy, current as of the FDA label accessed for this review in early 2025 (FDA drug approval database). That warning applies to an FDA-approved drug with a different pharmacologic profile than a GHRH secretagogue that works within the body's own feedback loop; somatostatin release provides a partial physiologic brake on GH secretagogue-driven IGF-1 elevation that does not exist in the same way with exogenous rhGH. This distinction is a plausible reason CJC-1295 may carry a different risk profile than rhGH, but it has not been established through dedicated long-term safety trials of GH secretagogues themselves.

Acromegaly results from years of chronically supraphysiologic GH and IGF-1 exposure. No published case reports linking CJC-1295 specifically to acromegaly were identified for this review as of early 2025, and the risk is generally considered low given the feedback-limited nature of secretagogue-driven GH release. This is an absence-of-evidence observation, not proof of absence of risk, and it is a reason periodic monitoring is still worthwhile rather than a reason to skip it.

What a baseline panel should generally include

Beyond IGF-1, a reasonable baseline workup before starting a GH secretagogue commonly includes fasting glucose and HbA1c (GH is counter-regulatory to insulin and can transiently worsen insulin sensitivity), a thyroid panel, a metabolic panel, and sex hormone levels relevant to the patient (testosterone in men, estradiol in women) to help interpret later IGF-1 changes. This list reflects general endocrine practice around GH-axis therapy rather than a peptide-specific published protocol, and the treating clinician should tailor it to the individual.

What is established, what is plausible, and what is not established

Established: CJC-1295 acts on the GHRH receptor and increases pulsatile GH secretion, which raises IGF-1 through hepatic conversion. IGF-1, not random GH, is the correct monitoring marker. The DAC and no-DAC forms have materially different half-lives and require different monitoring timing.

Plausible but not independently verified for this article: the specific percentage IGF-1 increases commonly attributed to single-dose DAC trials, the magnitude of additive effect when combining CJC-1295 with ipamorelin, and the exact monitoring intervals used across peptide-prescribing practices. These are reasonable working assumptions built on physiology and common practice, not confirmed trial outcomes as presented here.

Not established: long-term cancer risk directly caused by GH secretagogue use, real-world outcome data comparing monitoring strategies, and any FDA-recognized indication for CJC-1295 in humans. CJC-1295 remains an off-label or compounded product, and its overall safety and efficacy evidence base is smaller than for FDA-approved GH-axis therapies.

When to seek urgent evaluation

New severe headache, visual field changes, rapidly progressive joint or soft-tissue swelling, or signs of high blood glucose (excessive thirst, frequent urination) while on any GH secretagogue warrant prompt medical evaluation rather than waiting for a scheduled lab recheck.